KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $287.6 million.

  • Castle Biosciences' Cash & Current Investments rose 277.82% to $287.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $287.6 million, marking a year-over-year increase of 277.82%. This contributed to the annual value of $293.1 million for FY2024, which is 2058.05% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Cash & Current Investments is $287.6 million, which was up 277.82% from $275.9 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Cash & Current Investments ranged from a high of $407.0 million in Q1 2021 and a low of $225.5 million during Q2 2023
  • Moreover, its 5-year median value for Cash & Current Investments was $275.2 million (2025), whereas its average is $285.1 million.
  • In the last 5 years, Castle Biosciences' Cash & Current Investments soared by 31253.79% in 2021 and then plummeted by 2676.24% in 2022.
  • Over the past 5 years, Castle Biosciences' Cash & Current Investments (Quarter) stood at $329.6 million in 2021, then fell by 21.54% to $258.6 million in 2022, then fell by 6.0% to $243.1 million in 2023, then rose by 20.58% to $293.1 million in 2024, then dropped by 1.89% to $287.6 million in 2025.
  • Its last three reported values are $287.6 million in Q3 2025, $275.9 million for Q2 2025, and $275.2 million during Q1 2025.